Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil

被引:0
作者
Koper, Agnieszka [1 ,2 ]
Wilenski, Slawomir [3 ,4 ]
Sledzinska, Paulina [5 ]
Bebyn, Marek [5 ]
Koper, Krzysztof [2 ,6 ]
机构
[1] Nicolaus Copernicus Univ Torun, Dept Oncol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[2] Franciszek Lukaszczyk Oncol Ctr, Dept Oncol, PL-85796 Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ Torun, Dept Pharmaceut Technol, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
[4] Hosp Pharm, F Lukaszczyk Oncol Ctr, Cent Cytostat Drug Dept, PL-85796 Bydgoszcz, Poland
[5] 10th Mil Res Hosp & Polyclin, PL-85681 Bydgoszcz, Poland
[6] Nicolaus Copernicus Univ Torun, Dept Clin Oncol & Nursing, Dept Oncol Surg, Ludw Rydygier Coll Medicum, PL-85067 Bydgoszcz, Poland
关键词
Chemotherapy; Colorectal cancer; Prognostic factors; Trifluridine/Tipiracil; TAS-102; MONOTHERAPY; PLUS BEVACIZUMAB; DOUBLE-BLIND; OPEN-LABEL; HYPERTENSION; SURVIVAL; THERAPY; REGORAFENIB; CETUXIMAB; TRIAL;
D O I
10.1007/s00432-023-04909-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The systemic treatment options for metastatic colorectal cancer (mCRC) are unsatisfactory, and the disease recurs despite the use of numerous medications and their combinations. Trifluridine/Tipiracil is a relatively new drug used in refractory mCRC. Little is known about its real-world effectiveness and prognostic and predictive factors. Therefore, this study aimed to develop a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil. Methods We retrospectively evaluated the data from 163 patients who had received Trifluridine/Tipiracil as a third or fourth line of treatment for refractory mCRC. Results After starting Trifluridine/ Tipiracil, 21.5% of patients survived one year, and the median overall survival after Trifluridine/Tipiracil initiation was 251 days (SD: 17.855; 95%CI: 216-286). Median progression-free survival after Trifluridine/Tipiracil initiation was 56 days (SD: 4.826; 95%CI 47- 65). Moreover, the median overall survival from diagnosis was 1333 days (SD: 82.84; 95%CI: 1170-1495). In forward stepwise multivariate Cox regression analysis, initial radical treatment (HR = 0.552, 95% CI 0.372-0.819, p < 0.003), the number of cycles of first-line chemotherapy (HR = 0.978, 95% CI 0.961-0.995, p < 0.011), the number of cycles of second-line chemotherapy (HR = 0.955, 95% CI 0.931-0.98, p < 0.011), BRAF mutation (HR = 3.016, 95% CI = 1.207-7.537, p = 0.018), and hypertension (HR = 0.64, 95% CI = 0.44-0.931, p = 0.02) were all associated with survival after Trifluridine/Tipiracil initiation. Our model and model-based nomogram displayed an AUC of 0.623 for one-year survival estimation in the testing cohort. The C-index for the prediction nomogram was 0.632. Conclusion We have developed a prognostic model for refractory mCRC treated with Trifluridine/Tipiracil based on five variables. Moreover, we reported a nomogram which could be used by oncologists in clinic visits on a daily basis.y
引用
收藏
页码:10867 / 10877
页数:11
相关论文
共 50 条
[31]   Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan [J].
Kashiwa, Munenobu ;
Matsushita, Ryo .
CLINICAL THERAPEUTICS, 2020, 42 (07) :1376-1387
[32]   Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS) [J].
Hamers, Patricia A. H. ;
Vink, Geraldine R. ;
Elferink, Marloes A. G. ;
Stellato, Rebecca K. ;
Dijksterhuis, Willemieke P. M. ;
Punt, Cornelis J. A. ;
Koopman, Miriam ;
May, Anne M. .
CLINICAL COLORECTAL CANCER, 2022, 21 (02) :154-166
[33]   Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer [J].
Kotani, Daisuke ;
Kuboki, Yasutoshi ;
Horasawa, Satoshi ;
Kaneko, Asumi ;
Nakamura, Yoshiaki ;
Kawazoe, Akihito ;
Bando, Hideaki ;
Taniguchi, Hiroya ;
Shitara, Kohei ;
Kojima, Takashi ;
Tsuji, Akihito ;
Yoshino, Takayuki .
BMC CANCER, 2019, 19 (01)
[34]   Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada [J].
Samawi, H. H. ;
Brezden-Masley, C. ;
Afzal, A. R. ;
Cheung, W. Y. ;
Dolley, A. .
CURRENT ONCOLOGY, 2019, 26 (05) :319-+
[35]   A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer [J].
Andersen, Stig E. ;
Andersen, Ida B. ;
Jensen, Benny V. ;
Pfeiffer, Per ;
Ota, Takayo ;
Larsen, Jim S. .
ACTA ONCOLOGICA, 2019, 58 (08) :1149-1157
[36]   Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer [J].
Barone, Carlo ;
Di Bartolomeo, Maria ;
Lonardi, Sara ;
Maiello, Evaristo ;
Martinelli, Erika ;
Moretto, Roberto ;
Strippoli, Antonia ;
Tamburini, Emiliano ;
Zaniboni, Alberto ;
Pinto, Carmine .
FUTURE ONCOLOGY, 2021, 17 (14) :1749-1759
[37]   Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion [J].
Pinto, Carmine ;
Lonardi, Sara ;
Maiello, Evaristo ;
Martinelli, Erika ;
Prisciandaro, Michele ;
Salvatore, Lisa ;
Sartore-Bianchi, Andrea ;
Scartozzi, Mario ;
Aprile, Giuseppe ;
Cremolini, Chiara ;
Sobrero, Alberto .
FRONTIERS IN ONCOLOGY, 2025, 14
[38]   Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study [J].
Li, Rong-Rong ;
Zhou, Hui-Jun ;
Zeng, De-Yu ;
Jiang, Shao-Feng ;
Liu, Wu ;
Fruehling, Petter ;
Liu, Zhen-Yang .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) :612-629
[39]   Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer [J].
Burness, Celeste B. ;
Duggan, Sean T. .
DRUGS, 2016, 76 (14) :1393-1402
[40]   Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA Study [J].
Signorelli, Carlo ;
Calegari, Maria Alessandra ;
Anghelone, Annunziato ;
Passardi, Alessandro ;
Gallio, Chiara ;
Bittoni, Alessandro ;
Lucchetti, Jessica ;
Angotti, Lorenzo ;
Di Giacomo, Emanuela ;
Zurlo, Ina Valeria ;
Morelli, Cristina ;
Dell'Aquila, Emanuela ;
Artemi, Adele ;
Gemma, Donatello ;
Emiliani, Alessandra ;
Ribelli, Marta ;
Corsi, Domenico Cristiano ;
Arrivi, Giulia ;
Mazzuca, Federica ;
Zoratto, Federica ;
Chilelli, Mario Giovanni ;
Schirripa, Marta ;
Schietroma, Francesco ;
Morandi, Maria Grazia ;
Santamaria, Fiorenza ;
Dettori, Manuela ;
Cosimati, Antonella ;
Saltarelli, Rosa ;
Minelli, Alessandro ;
Lucci-Cordisco, Emanuela ;
Basso, Michele .
CANCERS, 2025, 17 (12)